R

Revance Therapeutics
D

RVNC

3.36000
USD
-0.415
(-10.99%)
مغلق
حجم التداول
41,562
الربح لكل سهم
0
العائد الربحي
0
P/E
-2
حجم السوق
604,247,039
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABT
    4.220
    (3.98%)
    110.150 USD
    BDX
    -4.995
    (-2.07%)
    236.055 USD
    B
    BHC
    0.07000
    (1.16%)
    6.10000 USD
    BSX
    1.315
    (1.78%)
    75.170 USD
    EW
    -1.220
    (-1.94%)
    61.830 USD
    ISRG
    6.98
    (1.57%)
    451.27 USD
    R
    RGEN
    -1.970
    (-1.18%)
    165.630 USD
    S
    SRPT
    1.650
    (1.16%)
    144.000 USD
    SYK
    5.59
    (1.71%)
    332.94 USD
الأخبار
المقالات

العنوان: Revance Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.